Aptose Biosciences Files 8-K on Financials

Ticker: APTOF · Form: 8-K · Filed: May 8, 2025 · CIK: 882361

Sentiment: neutral

Topics: financial-condition, results-of-operations, exhibits

Related Tickers: APTO

TL;DR

APTO filed an 8-K on May 8, 2025, detailing financial condition and results.

AI Summary

Aptose Biosciences Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.

Why It Matters

This 8-K filing provides investors with crucial updates on Aptose Biosciences' financial health and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s results of operations and financial condition, and to include financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on May 8, 2025.

What were Aptose Biosciences Inc.'s former names?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

In which jurisdiction is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

What is the Standard Industrial Classification code for Aptose Biosciences Inc.?

The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing